Vincerx Pharma, Inc.
DelistedCIK 1796129fmd_0A95KM7302MD2K7RQ7CD9XSW1QManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Dec 19, 2018 to Mar 31, 2025, 25 periods
| Line item | FY2020 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Research and development | – | 2 | 40 | 50 | 29 | 15 |
| Total operating expenses | – | 11 | 63 | 71 | 43 | 31 |
| Operating income | – | (11) | (63) | (71) | (43) | (31) |
| Interest expense | – | 0 | 0 | – | – | – |
| Interest and investment income | 0 | – | 0 | 1 | 1 | 0 |
| Other non-operating income (expense) | – | (6) | 23 | 8 | 2 | 1 |
| Income before taxes | (0) | – | (39) | (63) | (40) | (30) |
| Income tax expense | 0 | – | – | – | – | – |
| Net income from continuing operations | (0) | – | – | – | – | – |
| Net income | – | (17) | (39) | (63) | (40) | (30) |